A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Basit Öğe Kaydı
dc.contributor.authorAbali, Huseyin
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOnal, Cem
dc.contributor.authorDane, Faysal
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorMertsoylu, Huseyin
dc.date.accessioned2024-02-23T14:31:12Z
dc.date.available2024-02-23T14:31:12Z
dc.date.issued2018
dc.departmentNEÜen_US
dc.descriptionGastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) -- JAN 18-20, 2018 -- San Francisco, CAen_US
dc.description.abstract[Abstract Not Availabe]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1200/JCO.2018.36.4_suppl.26
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1200/JCO.2018.36.4_suppl.26
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15085
dc.identifier.volume36en_US
dc.identifier.wosWOS:000436174100026en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleA study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu